~!Q;U#X2$DCF[AZ]-V-P238UN%:$<L'R)5UU
SYSTEM PROCESSING...
~!Q;U#X2$DCF[AZ]-V-P238UN%:$<L'R)5UU
SYSTEM PROCESSING...
Posted: 2025-05-01 20:52:32 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-05-01 20:52:49 UTC
Verified By
Rollup News
Semaglutide, found in the weight-loss drug Ozempic, shows promising results in treating MASH, a liver disease linked to obesity and diabetes, by reducing liver inflammation and scarring. Lifestyle changes are crucial for the drug's effectiveness. Novo Nordisk aims for EU approval in 2025, as there are currently no approved drugs for MASH in the EU.
Semaglutide's potential in treating MASH
Importance of lifestyle changes alongside medication
Novo Nordisk's push for EU approval in 2025
MASH has no EU-approved drugs yet
Effectiveness depends on lifestyle changes